Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC

Exclusion Criteria

• •Previously received systemic anti-tumor therapy for non-small cell lung cancer.
• •history or current (non-infectious) pneumonia/interstitial pneumonia requiring steroid treatment.
• •History or active pulmonary tuberculosis.
• •Active infections that require systemic treatment.
• •History or suspected autoimmune disease or immune deficiency who, in the judgment of the investigator, cannot tolerate immunotherapy.
• •Untreated active Hepatitis B.
• •Has a known history of human immunodeficiency virus (HIV) infection (HIV 1/2 antibody positive).
• •Grade 3 or above peripheral neuropathy.
• •Severe allergic history to pemetrexed, paclitaxel, albumin-bound paclitaxel, carboplatin or other preventive drugs.
• •Underlying severe or uncontrolled disease.
• •Malignant tumors other than NSCLC within 5 years.
• •Any medical condition requiring systemic treatment with corticosteroids (prednisone or equivalent at a dose of \>10mg/ day) or other immunosuppressive agents within 14 days prior to treatment.